Program
CK-0802
Also written as “CK0801”, “CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)” and “CK0802”.
Its studies are mostly in Bone Marrow Diseases · Graft vs Host Disease · Anemia, Aplastic · Guillain-Barre Syndrome · COVID-19, led by Cellenkos.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cellenkos | 53 open or running | phase 2since Mar 24, 2026 | Oct 23, 2018 | May 25, 2027phase 1 · NCT03773393 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2018First studies: 2 phase 1 studiesFirst studyNCT03773393, NCT03773328
- Jul 10, 2020Phase 1 study in COVID-19NCT04468971 · 45 enrolled · United States
- Mar 24, 2026Phase 2 study in Anemia, AplasticPhase 2 reachedNCT07499102 · 12 planned
- May 1, 2026Phase 2 study in Graft vs Host DiseaseNCT07576699 · 12 planned
Ahead
- May 25, 2027Primary completion: phase 1 study in Bone Marrow DiseasesNCT03773393
- Jun 30, 2028Primary completion: phase 2 study in Graft vs Host DiseaseNCT07576699
- Aug 3, 2028Primary completion: phase 2 study in Anemia, AplasticNCT07499102
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07576699Graft vs Host Disease | 2 | Not yet recruiting | Jun 30, 2028 | 12 |
| NCT07499102Anemia, Aplastic | 2 | Not yet recruiting | Aug 3, 2028 | 12 |
| NCT04468971COVID-19 · United States | 1 | Completed | Oct 22, 2021 | 45 |
| NCT03773393Bone Marrow Diseases · United States | 1 | Active, not recruiting | May 25, 2027 | 18 |
| NCT03773328Guillain-Barre Syndrome | 1 | Withdrawn | Feb 2025 | 0 |
How it is read
Names in the registry
- “CK0801”, 3 entries
- “CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)”, 1 entry
- “CK0802”, 1 entry
Conditions, from the studies’ own filings
- Bone Marrow Diseases, 1 study
- Graft vs Host Disease, 1 study
- Anemia, Aplastic, 1 study
- Guillain-Barre Syndrome, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.